News

Wed, 17/05/2017
Swedish Data on Rituximab – Presentation by Fredrik Piehl
Munich. Sweden is the only country where the MS treatment Rituximab is frequently used even if it has not been formally approved. The neuroimmunologist mainly responsible for this fact is MS researcher Fredrik Piehl from Karolinska Institutet in Stockholm/Sweden. His research group provided observational data on Rituximab therapy and will now start a large clinical […]...more
Wed, 17/05/2017
Hematopoietic Stem Cell Niche and Cell Signaling
Mainz. Borhane Guezguez (Mainz/Frankfurt/Heidelberg) has recently become head of a scientific working group at UCI. He will present his work in a lecture on “Hematopoietic Stem Cell Niche and Cell Signaling: From Biological Aspects To Therapeutic Perspectives” Time: Wednesday, 17th of May,5:15pm Place: Building 708, SR2, University Medical Center, Langenbeckstr. 1, Mainz...more
Wed, 17/05/2017
Lecture: MS: Can we develop therapies?
Muenster. The Department of Neurology is happy to announce that Dr. Susan Goelz will give a lecture as part of the Neurological Seminar. Time: Wednesday, 17th of May, 6:15pm Place: Large conference room, Level 05 West in the central clinics building, Albert-Scweitzer-Campus 1, Building A 1, 48149 Muenster Title of her talk: „Putative pathways leading […]...more


Wed, 17/05/2017 | Lecture: MS: Can we develop therapies?

Muenster. The Department of Neurology is happy to announce that Dr. Susan Goelz will give a lecture as part of the Neurological Seminar.

Time: Wednesday, 17th of May, 6:15pm
Place: Large conference room, Level 05 West in the central clinics building, Albert-Scweitzer-Campus 1, Building A 1, 48149 Muenster

Title of her talk: „Putative pathways leading to neurodegeneration in MS:  Can we develop therapies?”

After her time as a Postdoc, Susan Goelz was working as a scientist and manager in the pharmaceutical industry, first at Biogen (from 1988 on), then at Elan Pharmaceuticals. In her time at Biogen, she was responsible for the development and market introduction / approval process of Interferon-beta (Avonex), which has been one of the most successful MS therapies since its FDA approval in 1995. In addition to her post as a lecturer at Oregon Health and Sciences University, she works as a consultant for pharmaceutical companies and specializes in translational medicine, as well as networking between academia and pharmaceutical industries. She has connections all over the world and expertise in the newest techniques, disease models, and treatment options.